BioCentury
ARTICLE | Finance

Progenics chronicles

April 28, 2008 7:00 AM UTC

Progenics' stock has had a bumpy ride from the newsflow related to the methylnaltrexone compound it in-licensed from UR Labs in 2001. The company ended last week up 95% - gaining $6.52 to $13.40 - on ...